ASCO 2021: Pembrolizumab shows promise for adjuvant treatment of renal cell carcinoma

Written by | 18 Jun 2021

Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of  kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June […]

ASCO 2021: Adjuvant olaparib PARP improves outcomes in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

Written by | 17 Jun 2021

When treated with adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy, patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, […]

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.